↓ Skip to main content

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial

Overview of attention for article published in European Journal of Cancer (1965), August 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
53 Mendeley
Title
Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial
Published in
European Journal of Cancer (1965), August 2016
DOI 10.1016/j.ejca.2016.04.024
Pubmed ID
Authors

Michail Ignatiadis, Brigitte Rack, Francoise Rothé, Sabine Riethdorf, Charles Decraene, Hervé Bonnefoi, Christian Dittrich, Carlo Messina, Melanie Beauvois, Elisabeth Trapp, Theodora Goulioti, Konstantinos Tryfonidis, Klaus Pantel, Madeline Repollet, Wolfgang Janni, Martine Piccart, Christos Sotiriou, Saskia Litiere, Jean-Yves Pierga

Abstract

There is increasing evidence that breast cancer evolves over time under the selection pressure of systemic treatment. Today, treatment decisions in early breast cancer are based on primary tumour characteristics without considering the disease evolution. Chemoresistant micrometastatic disease is poorly characterised and thus it is not used in current clinical practice as a tool to personalise treatment approaches. The detection of chemoresistant circulating tumour cells (CTCs) has been shown to be associated with worse prognosis in early breast cancer. The ongoing Treat CTC trial is the first international, liquid biopsy-based trial evaluating the concept of targeting chemoresistant minimal residual disease: detection of CTCs following adjuvant chemotherapy (adjuvant cohort) or neoadjuvant chemotherapy in patients who did not achieve pathological complete response (neoadjuvant cohort). This article presents the rational and design of this trial and the results of the pilot phase after 350 patients have been screened and provides insights that might provide information for future trials using the liquid biopsy approach as a tool towards precision medicine (NCT01548677).

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 2%
Israel 1 2%
Unknown 51 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 11 21%
Researcher 10 19%
Student > Ph. D. Student 9 17%
Student > Doctoral Student 7 13%
Other 7 13%
Other 9 17%
Readers by discipline Count As %
Medicine and Dentistry 16 30%
Biochemistry, Genetics and Molecular Biology 13 25%
Unspecified 8 15%
Agricultural and Biological Sciences 7 13%
Computer Science 2 4%
Other 7 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2017.
All research outputs
#9,394,561
of 12,247,359 outputs
Outputs from European Journal of Cancer (1965)
#3,098
of 3,753 outputs
Outputs of similar age
#176,828
of 275,410 outputs
Outputs of similar age from European Journal of Cancer (1965)
#46
of 74 outputs
Altmetric has tracked 12,247,359 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,753 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,410 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.